Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Eyes Longer-Lasting Stomach Acid Drug (Japan)

This article was originally published in PharmAsia News

Executive Summary

Eisai Co. is working on a follow-up to Pariet, its drug for stomach ulcers, acid reflux, and related gastrointestinal problems. U.S. patents on Pariet, which is sold in America as Aciphex, expire in May 2013. Eisai hopes to have the new product ready by May 2013, when U.S. patents on the drug, which is marketed in the United States as Aciphex, expire. Eisai says the new drug will be longer-lasting and more effective than Pariet at blocking secretion of stomach acid at night. The third and final phase of clinical testing will begin as early as 2008 in the U.S. The company plans to apply for marketing approval in fiscal 2009. (Click here for more - May Require Paid Subscription

You may also be interested in...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts